计算溶液所需的质量、体积或浓度。
Lutikizumab (anti-IL1a&IL1b) (Ab175588) - ELISA
Immobilized Recombinant Human IL-1 alpha protein (rp156178) at 1.0 μg/mL can bind Lutikizumab (anti-IL1a&IL1b) (Ab175588) with the EC50 of 38.93 ng/mL.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| Ab175588-100μg |
100μg |
现货 ![]() |
| |
| Ab175588-1mg |
1mg |
现货 ![]() |
| |
| Ab175588-5mg |
5mg |
现货 ![]() |
| |
| Ab175588-10mg |
10mg |
期货 ![]() |
|
| 产品名称 | Lutikizumab (anti-IL1a&IL1b), 白细胞介素-1α抑制剂 |
|---|---|
| 别名 | 鲁吉珠单抗 | 鲁吉珠单抗 | 鲁替珠单抗(抗 IL1a 和 IL1b) |
| 英文别名 | BAF antibody | FAF antibody | Hematopoietin 1 antibody | Hematopoietin-1 antibody | IL 1 alpha antibody | IL 1A antibody | IL-1 alpha antibody | Il-1a antibody | IL1 ALPHA antibody | IL1 antibody | IL1A antibody | IL1A_HUMAN antibody | IL1F1 antibody | In |
| 规格或纯度 | 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥90%(SDS-PAGE&SEC-HPLC), 见COA |
| 宿主种属 | 人(Human) |
| 特异性 | IL1A & IL1B |
| 种属反应性 | 人(Human),小鼠(Mouse),食蟹猴(Cynomolgus monkey) |
| 偶联 | Unconjugated |
| 作用类型 | 抑制剂 |
| 作用机制 | 白细胞介素-1α抑制剂 |
| 克隆类型 | 重组抗体 |
|---|---|
| Format | Whole IgG |
| 亚型 | Human IgG1 |
| 轻链亚型 | kappa |
| SDS-PAGE | 196.8 kDa |
| 纯化方法 | Protein A purified |
| 防腐剂 | No |
| 浓度 | 见COA |
| 储存温度 | -80℃储存,避免反复冻融 |
| 运输条件 | 超低温冰袋运输 |
| 稳定性与储存 | 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。 |
| CAS编号和信息 | 1791411-57-8 |
| 分子类型 | 抗体 |
Lutikizumab (anti-IL1a&IL1b) (Ab175588) - ELISA
Immobilized Recombinant Human IL-1 alpha protein (rp156178) at 1.0 μg/mL can bind Lutikizumab (anti-IL1a&IL1b) (Ab175588) with the EC50 of 38.93 ng/mL.
Lutikizumab (anti-IL1a&IL1b) (Ab175588) - SEC
The purity of Lutikizumab (anti-IL1a&IL1b) (Ab175588) is more than 95% verified by HPLC.
通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!
| 批号(Lot Number) | 证书类型 | 日期 | 货号 |
|---|---|---|---|
| 分析证书 | 24-11-05 | Ab175588 | |
| 分析证书 | 24-11-05 | Ab175588 | |
| 分析证书 | 24-11-05 | Ab175588 |
| 1. Dayer JM, Graham R, Russell G, Krane SM. (1977) Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor.. Science, 195 (4274): (181-3). [PMID:188134] |
| 2. DiGiammarino E, Ghayur T, Liu J. (2012) Design and generation of DVD-Ig™ molecules for dual-specific targeting.. Methods Mol Biol, 899 (145-56). [PMID:22735951] |
| 3. Lacy SE, Wu C, Ambrosi DJ, Hsieh CM, Bose S, Miller R, Conlon DM, Tarcsa E, Chari R, Ghayur T et al.. (2015) Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig(TM)) molecule that specifically and potently neutralizes both IL-1α and IL-1β.. MAbs, 7 (3): (605-19). [PMID:25764208] |
| 4. Wang SX, Abramson SB, Attur M, Karsdal MA, Preston RA, Lozada CJ, Kosloski MP, Hong F, Jiang P, Saltarelli MJ et al.. (2017) Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study.. Osteoarthr Cartil, 25 (12): (1952-1961). [PMID:28964890] |
| 5. Goldring MB, Birkhead J, Sandell LJ, Kimura T, Krane SM. (1988) Interleukin 1 suppresses expression of cartilage-specific types II and IX collagens and increases types I and III collagens in human chondrocytes.. J Clin Invest, 82 (6): (2026-37). [PMID:3264290] |
| 6. Goldring MB, Krane SM. (1987) Modulation by recombinant interleukin 1 of synthesis of types I and III collagens and associated procollagen mRNA levels in cultured human cells.. J Biol Chem, 262 (34): (16724-9). [PMID:3500170] |
| 7. Dayer JM, Roelke MS, Krane SM. (1984) Effects of prostaglandin E2, indomethacin, trifluoperazine and drugs affecting the cytoskeleton on collagenase production by cultured adherent rheumatoid synovial cells.. Biochem Pharmacol, 33 (18): (2893-9). [PMID:6089839] |
| 8. McGuire-Goldring MB, Meats JE, Wood DD, Ihrie EJ, Ebsworth NM, Russell RG. (1984) In vitro activation of human chondrocytes and synoviocytes by a human interleukin-1-like factor.. Arthritis Rheum, 27 (6): (654-62). [PMID:6610426] |